129 related articles for article (PubMed ID: 16682201)
1. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
[TBL] [Abstract][Full Text] [Related]
2. Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2.
Maier JA; Brugel TA; Clark MP; Sabat M; Golebiowski A; Bookland RG; Laufersweiler MJ; Laughlin SK; Vanrens JC; De B; Hsieh LC; Brown KK; Juergens K; Walter RL; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(13):3514-8. PubMed ID: 16632350
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
5. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
[TBL] [Abstract][Full Text] [Related]
6. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
[TBL] [Abstract][Full Text] [Related]
7. Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.
Brugel TA; Maier JA; Clark MP; Sabat M; Golebiowski A; Bookland RG; Laufersweiler MJ; Laughlin SK; Vanrens JC; De B; Hsieh LC; Mekel MJ; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(13):3510-3. PubMed ID: 16632356
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
[TBL] [Abstract][Full Text] [Related]
10. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
[TBL] [Abstract][Full Text] [Related]
11. Disubstituted pyrimidines as Lck inhibitors.
Hunt JA; Beresis RT; Goulet JL; Holmes MA; Hong XJ; Kovacs E; Mills SG; Ruzek RD; Wong F; Hermes JD; Park YW; Salowe SP; Sonatore LM; Wu L; Woods A; Zaller DM; Sinclair PJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5440-3. PubMed ID: 19674899
[TBL] [Abstract][Full Text] [Related]
12. New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
Gommermann N; Buehlmayer P; von Matt A; Breitenstein W; Masuya K; Pirard B; Furet P; Cowan-Jacob SW; Weckbecker G
Bioorg Med Chem Lett; 2010 Jun; 20(12):3628-31. PubMed ID: 20483608
[TBL] [Abstract][Full Text] [Related]
13. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
[TBL] [Abstract][Full Text] [Related]
14. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
[TBL] [Abstract][Full Text] [Related]
15. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
16. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
[TBL] [Abstract][Full Text] [Related]
17. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
Das J; Chen P; Norris D; Padmanabha R; Lin J; Moquin RV; Shen Z; Cook LS; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; McIntyre KW; Shuster DJ; Gillooly KM; Behnia K; Schieven GL; Wityak J; Barrish JC
J Med Chem; 2006 Nov; 49(23):6819-32. PubMed ID: 17154512
[TBL] [Abstract][Full Text] [Related]
18. A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.
Borhani DW; Calderwood DJ; Friedman MM; Hirst GC; Li B; Leung AK; McRae B; Ratnofsky S; Ritter K; Waegell W
Bioorg Med Chem Lett; 2004 May; 14(10):2613-6. PubMed ID: 15109663
[TBL] [Abstract][Full Text] [Related]
19. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel 4,5-diphenylthiazole derivatives as potential acyl-CoA:cholesterol O-acyltransferase inhibitors.
Romeo G; Salerno L; Milla P; Siracusa M; Cattel L; Russo F
Pharmazie; 1999 Jan; 54(1):19-23. PubMed ID: 9987793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
